UM  > Faculty of Law
Off-label use of medicines under scrutiny: Between competition law and pharma regulations
Source PublicationMedicine and Law

The off-label use of medicines was discussed from various angles including sector-specific regulations, pharmacovigilance obligations, organization of the national health care systems and professional ethics. The recourse to off-label use of medicinal products is gaining importance as national health budgets are shrinking and governments are looking for more affordable means to supply health care to their citizens. Any relevant legislation or judicial interpretation should be analyzed in the light of the public health objectives. The present paper deals with the off-label use of medicines under EU competition law, through the discussion of the F Hoffman-La Roche et al v AutoritA garante della concorrenza e del mercato case, which the European Court of Justice (ECJ) has recently addressed in its explanatory ruling. The case originated from the investigation of the Italian competition authority prosecuting the anti-competitive collusion related to the suppression of the off-label use. The paper addresses the regulatory framework for off-label use in the EU and the likely effects of the ECJ's interpretation concerning pharma companies' involvement in monitoring and reporting possible health risks related to the off-label use. It demonstrates that the differences in regulatory approaches, across EU Member States, could lead to the diverging competitive conditions on the national markets for prescription drugs, reimbursed under the national health insurance systems. As a result, the competition law cases, concerning off-label use of medicinal products, would have to take into account the national specifics of these markets.

KeywordCompetition Law European Union Off-label Prescription Off-label Promotion Pharmaceuticals Pharmacovigilance
URLView the original
Indexed By其他
WOS Research AreaGovernment & Law
WOS SubjectLaw
WOS IDWOS:000495912100003
Scopus ID2-s2.0-85070508515
Fulltext Access
Citation statistics
Cited Times [WOS]:0   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Law
Corresponding AuthorSvetlicinii,Alexandr
AffiliationUniversity of Macau, Faculty of Law, Macao
First Author AffilicationFaculty of Law
Corresponding Author AffilicationFaculty of Law
Recommended Citation
GB/T 7714
Svetlicinii,Alexandr. Off-label use of medicines under scrutiny: Between competition law and pharma regulations[J]. Medicine and Law,2019,38(2):165-182.
APA Svetlicinii,Alexandr.(2019).Off-label use of medicines under scrutiny: Between competition law and pharma regulations.Medicine and Law,38(2),165-182.
MLA Svetlicinii,Alexandr."Off-label use of medicines under scrutiny: Between competition law and pharma regulations".Medicine and Law 38.2(2019):165-182.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Svetlicinii,Alexandr]'s Articles
Baidu academic
Similar articles in Baidu academic
[Svetlicinii,Alexandr]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Svetlicinii,Alexandr]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.